SEC Form 6-K filed by Redhill Biopharma Ltd.
Commission File No.:001-35773
1. |
To appoint Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as the Company’s auditors for the year 2025 and for an additional period until the next Annual
General Meeting;
|
2. |
To approve the re-election of Mr. Dror Ben-Asher and Dr. Kenneth Reed to the board of directors of the Company (the “Board of Directors”) for an additional three-year term until the annual general meeting to be held in 2028;
|
3. |
To approve a renewal of an amended version of the Company’s compensation policy for a three-year period in accordance with the requirements of the Israeli Companies Law, 5759-1999;
|
4. |
To approve the grant of restricted share units (“RSUs”) each with respect to one American Depository Share (each representing 10,000 ordinary shares, par value NIS 0.01 each) to the non-executive directors of the Company;
|
5. |
To approve the grant of RSUs to Mr. Dror Ben-Asher, the Company’s Chief Executive Officer and Chairman of the Board of Directors;
|
6. |
To approve the grant of RSUs to Mr. Rick D. Scruggs, the Company’s Chief Commercial Officer, and Director; and
|
7. |
To approve an increase in the Company’s authorized share capital.
|
|
REDHILL BIOPHARMA LTD.
|
|
|
|
(the “Registrant”)
|
|
|
|
|
|
|
Date: May 27, 2025
|
By:
|
/s/ Dror Ben-Asher
|
|
|
Name:
|
Dror Ben-Asher
|
|
|
Title:
|
Chief Executive Officer
|
|